

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

TotalSeq(TM)-C0138 anti-human CD5

RRID:AB_2800726

Type: Antibody

Proper Citation

BioLegend Cat# 300637, RRID:AB_2800726

Antibody Information

URL: http://antibodyregistry.org/AB_2800726

Proper Citation: BioLegend Cat# 300637, RRID:AB_2800726

Target Antigen: CD5

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: PG

Antibody Name: TotalSeq(TM)-C0138 anti-human CD5

Description: This monoclonal targets CD5

Target Organism: human

Clone ID: Clone UCHT2

Antibody ID: AB_2800726

Vendor: BioLegend

Catalog Number: 300637

Record Creation Time: 20231110T032756+0000

Record Last Update: 20260829T100311+0000

Ratings and Alerts

No rating or validation information has been found for TotalSeq(TM)-C0138 anti-human CD5.

No alerts have been found for TotalSeq(TM)-C0138 anti-human CD5.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Lee H, et al. (2025) TCR signaling via NFATc1 constrains IL-15-induced bystander activation of human memory CD8+ T cells. Immunity, 58(12), 2957.

Buus TB, et al. (2025) Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer. Cancer discovery, 15(10), 2036.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell reports. Medicine, 5(7), 101628.

Ivanova EN, et al. (2023) mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. iScience, 26(12), 108572.

Bachiredy P, et al. (2021) Mapping the evolution of T??cell states during response and resistance to adoptive cellular therapy. Cell reports, 37(6), 109992.